healthcare stocks Archives

Doctor reviewing healthcare data on a tablet beside a desktop displaying digital health tools at a hospital workstation

Doximity’s UpToDate Deal and Amwell’s Mental Health Results Build a Bullish Case for Connected Care -( $AMWL $DOCS $DCYHY $WTKWY )

by John F. Heerdink, Jr. October 21, 2026 404Views 0Likes

Clinical AI gains an authoritative partner as digital therapy delivers measurable results, giving investors fresh reasons to watch DOCS, AMWL, WKL and DCYHY. Healthcare technology has spent years promising to make medicine faster, smarter and less expensive. Two recent developments suggest parts…

Vintage comic-style illustration of a Viking warrior holding a $575 million money bag, symbolizing Viking Therapeutics’ obesity drug development ambitions.

Viking Therapeutics’ $575 Million Raise Gives Its Obesity Ambitions New Muscle -( $VKTX $IBB $XBI )

by John F. Heerdink, Jr. October 20, 2026 274Views 0Likes

With oral VK2735 entering Phase 3 and injectable trials fully enrolled, Viking Therapeutics (NASDAQ: VKTX) is building a broader case in weight management. Viking Therapeutics (NASDAQ: VKTX) has strengthened two foundations of its obesity-drug investment story: the capital to advance its programs…

Illustration of a circuit-covered Wall Street bull above a market chasm, beneath an AI brain and inflation tornado, with a $2 trillion label.

Weekly Market Summary – October 16, 2026: Nasdaq Falls 4.5% as AI Jitters, Inflation and a $2 Trillion Deficit Test Wall Street -( $EPRX $MODD $NVDA $SER $SPCX $TRV $TSLA )

by John F. Heerdink, Jr. October 16, 2026 181311Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Trading-floor monitor displaying McKesson and Option Care Health logos, a $5.8 billion deal headline and an upward arrow representing home infusion growth.

McKesson’s $5.8 Billion Option Care Deal Puts Home Infusion in Wall Street’s Spotlight -( $MCK $OPCH )

by John F. Heerdink, Jr. October 6, 2026 825Views 0Likes

The proposed acquisition offers Option Care Health shareholders a substantial cash premium, and gives McKesson a strategic foothold in delivering complex therapies closer to patients. McKesson Corporation (NYSE: MCK) and private investment firm Clayton, Dubilier & Rice are making a $5.8 billion…

Alt Text: Illustration of the Nobel Prize in Medicine lighting a new bull market for brain science, featuring a glowing brain, neural connections, a rising stock-market chart and a charging digital bull above a city skyline as researchers look on.

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

by John F. Heerdink, Jr. October 5, 2026 384Views 0Likes

The 2026 Nobel Prize in Physiology or Medicine has put optogenetics, the science of using light to control precisely selected nerve cells, squarely in the global spotlight. For many, the award is more than a ceremonial victory lap for academic neuroscience:…

Illustration of a glowing green Nasdaq-themed cobra rising beside upward stock-market charts on a trading floor, representing the October 5, 2026 technology-led market rally as investors look past higher Treasury yields and a cautious bond market.

Stock Market Today, October 5, 2026: Nasdaq Leads Rally as Tech Ignores Bond-Market Side-Eye -( $AMWL $AZN $DOCS $EPRX $LPL $MODD $NVDA $SER $SMMT $SPCX $TSLA $TSM )

by John F. Heerdink, Jr. October 5, 2026 146254Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN )

by John F. Heerdink, Jr. October 3, 2026 418Views 0Likes

Parabilis Medicines, Inc. (NASDAQ: PBLS) entered public markets with the kind of financial runway, strategic endorsement and clinical ambition that tends to make biotech investors sit up straighter in their Aeron chairs. The Cambridge-based clinical-stage company is pursuing a deceptively simple proposition: use…

Comic-book-style illustration highlighting pharma, space and AI investment themes: a Bayer research lab in Ohio, a SpaceX rocket launching from an Ohio-inspired Starbase, and Eupraxia displayed over an AI-powered global network, beneath the headline “Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up.”

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

by John F. Heerdink, Jr. October 3, 2026 358Views 0Likes

The Market’s Growth Engines Are Getting Physical Wall Street has spent years rewarding promises around artificial intelligence, advanced medicine and space infrastructure. This week, the narrative acquired something investors usually appreciate even more: concrete evidence of execution. Bayer AG (OTC: BAYRY) is…

Business analysts review Eupraxia Pharmaceuticals’ EP-104GI clinical data, including symptom reduction and histological-response visuals, alongside an investment calendar highlighting the anticipated December 2026 RESOLVE trial milestone.

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. October 2, 2026 724Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…

Cartoon-style Wall Street trading floor scene featuring a smiling bull in a pinstripe suit holding a phone with a rising green chart, surrounded by applauding traders, confetti and market screens highlighting cooling inflation, booming AI demand, consumer resilience and an advancing S&P 500.

Cooling Inflation, AI Demand and Consumer Resilience: Why Wall Street’s Bull Case May Be Getting Stronger -( $AAPL $AMZN $CVS $ELV $MCD $NVDA $SKHY $UNH )

by John F. Heerdink, Jr. September 30, 2026 369Views 0Likes

A steadier labor market, cooler-than-expected inflation, fresh consumer purchasing power, evolving digital-advertising models and disciplined corporate cost management are creating a more constructive backdrop for equities. The economy is not behaving like a fireworks display, but for investors that may be the…

Tag: healthcare stocks

Doximity’s UpToDate Deal and Amwell’s Mental Health Results Build a Bullish Case for Connected Care -( $AMWL $DOCS $DCYHY $WTKWY )

Viking Therapeutics’ $575 Million Raise Gives Its Obesity Ambitions New Muscle -( $VKTX $IBB $XBI )

Weekly Market Summary – October 16, 2026: Nasdaq Falls 4.5% as AI Jitters, Inflation and a $2 Trillion Deficit Test Wall Street -( $EPRX $MODD $NVDA $SER $SPCX $TRV $TSLA )

McKesson’s $5.8 Billion Option Care Deal Puts Home Infusion in Wall Street’s Spotlight -( $MCK $OPCH )

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

Stock Market Today, October 5, 2026: Nasdaq Leads Rally as Tech Ignores Bond-Market Side-Eye -( $AMWL $AZN $DOCS $EPRX $LPL $MODD $NVDA $SER $SMMT $SPCX $TSLA $TSM )

The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN )

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

Cooling Inflation, AI Demand and Consumer Resilience: Why Wall Street’s Bull Case May Be Getting Stronger -( $AAPL $AMZN $CVS $ELV $MCD $NVDA $SKHY $UNH )

Your Guide To Staying Informed In The Markets